eEF2K enhances expression of PD-L1 by promoting the translation of its mRNA by Wu, Y. et al.
Research Article
eEF2K enhances expression of PD-L1 by promoting
the translation of its mRNA
Yu Wu1,*, Jianling Xie2,*, Xin Jin1,2, Roman V. Lenchine2,3, Xuemin Wang2,3, Danielle M. Fang2,3,
Zeyad D. Nassar4,5, Lisa M. Butler4,5, Jing Li1,6 and Christopher G. Proud2,3
1Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Yushan Road, Qingdao, China; 2Lifelong Health,
South Australian Health and Medical Research Institute, North Terrace, Adelaide, SA 5000, Australia; 3School of Biological Sciences, University of Adelaide, Adelaide, SA 5005,
Australia; 4Adelaide Medical School and Freemasons Foundation Centre for Men’s Health, University of Adelaide, Adelaide, SA 5005, Australia; 5Precision Medicine, South
Australian Health and Medical Research Institute, Adelaide, SA 5001, Australia; 6Laboratory for Marine Drugs and Bioproducts of Qingdao National Laboratory for Marine Science
and Technology, Qingdao, China
Correspondence: Jing Li (lijing_ouc@ouc.edu.cn) or Christopher G. Proud (Christopher.Proud@sahmri.com)
Emerging advances in cancer therapy have transformed the landscape towards cancer
immunotherapy regimens. Recent discoveries have resulted in the development of clinical
immune checkpoint inhibitors that are ‘game-changers’ for cancer immunotherapy. Here
we show that eEF2K, an atypical protein kinase that negatively modulates the elongation
stage of protein synthesis, promotes the synthesis of PD-L1, an immune checkpoint
protein which helps cancer cells to escape from immunosurveillance. Ablation of eEF2K
in prostate and lung cancer cells markedly reduced the expression levels of the PD-L1
protein. We show that eEF2K promotes the association of PD-L1 mRNAs with translation-
ally active polyribosomes and that translation of the PD-L1 mRNA is regulated by a uORF
(upstream open reading-frame) within its 50-UTR (50-untranslated region) which starts with
a non-canonical CUG as the initiation codon. This inhibitory effect is attenuated by
eEF2K thereby allowing higher levels of translation of the PD-L1 coding region and
enhanced expression of the PD-L1 protein. Moreover, eEF2K-depleted cancer cells are
more vulnerable to immune attack by natural killer cells. Therefore, control of translation
elongation can modulate the translation of this specific mRNA, one which contains an
uORF that starts with CUG, and perhaps others that contain a similar feature. Taken
together, our data reveal that eEF2K regulates PD-L1 expression at the level of the trans-
lation of its mRNA by virtue of a uORF in its 50-region. This, and other roles of eEF2K in
cancer cell biology (e.g. in cell survival and migration), may be exploited for the design of
future therapeutic strategies.
Introduction
It is now clear that immunotherapy is a promising and effective approach to tackling a range of
cancers (reviewed [1]). However, cancer cells can resist immune attack through so-called checkpoints,
the two most-widely studied of which are programmed cell death protein 1 (PD-1) and cytotoxic
T-lymphocyte protein 4 [1]. PD-1, which is expressed on the surface of T lymphocytes, binds ligands
expressed on other cells which, through PD-1, repress the activity of T cells. One such ligand is the
protein PD-ligand 1 (PD-L1; [1], also termed CD274) which can be induced by signals such as
interferon-γ (IFNγ), a cytokine. It is increasingly clear that countering these so-called immune check-
points promotes immune responses, including against cancer cells. Indeed, antibodies that block either
PD-1 or PD-L1 have shown striking efficacy in tackling a number of cancers (see, e.g. [1]).
As such, it is important to understand the mechanisms that control the expression of PD-L1 on
cancer cells and thus enable them to ‘hide’ from immune surveillance. The expression of PD-L1 is
known to be controlled at multiple levels including transcription of its gene, the stability of its mRNA
and by microRNAs [1,2].
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mRNA translation is subject to control by a range of sophisticated mechanisms downstream of multiple sig-
nalling pathways [3]. One such mechanism involves the modulation of the rate of the elongation phase of
protein synthesis through the phosphorylation of eukaryotic elongation factor 2 (eEF2) by its cognate kinase,
eEF2K. eEF2K is an atypical, Ca2+-dependent protein kinase which is activated under diverse stress conditions
and is turned off by signalling through the anabolic mechanistic target of rapamycin complex 1 (mTORC1) sig-
nalling pathway [4]. Importantly, eEF2K is not required for mammalian viability, fertility or health under
normal vivarium conditions [5], meaning that agents that block its activity are not expected to exert adverse
on-target effects.
Interestingly, eEF2K plays role in tumour cell survival during nutrient depletion, probably by slowing down
protein synthesis and thereby reducing the consumption of energy and amino acids [6–8] and in cancer cell
migration and angiogenesis, by regulating the synthesis of proteins involved in this process including some
integrins [9,10]. Indeed, a number of studies have shown that eEF2K activity and/or alteration of translation
elongation rates affects the translation of specific mRNAs and thus the synthesis of individual types of proteins
(e.g. [9,11,12]), although the mechanisms underlying this have remained unclear.
Here we show, for the first time, that the expression of the PD-L1 protein is promoted by eEF2K, whose
only validated substrate is eEF2, implying that this occurs via control the translation elongation machinery. We
show that this involves a novel mechanism whereby eEF2K, suppresses the effect of an inhibitory upstream
open reading-frame (uORF). This raises the possibility that other members of the set of mRNAs that contain
such features [13] may also be controlled by eEF2K. Other, previously identified uORF-regulated mRNAs are
controlled in a quite different way, via the translation initiation factors eIF2 and eIF2B [14].
These findings further strengthen the rationale that eEF2K is a potentially valuable target for cancer therapy,
reflecting its role in processes including immune surveillance, as well as cell survival and cell migration.
Materials and methods
Chemicals and reagents
All chemicals were from Merck (Frenchs Forest, NSW, Australia) unless otherwise specified. Human interferon
γ (IFNγ), rapamycin and eFT508 were purchased from Jomar Life Research (Scoresby, Australia).
Cell culture, treatment and lysis
Cell line authentications were performed by Garvan Molecular Genetics (Darlinghurst, NSW, Australia) and
CellBank Australia (Westmead, NSW, Australia) for A549 and PC3 cells, respectively. Cells were routinely
tested against mycoplasma contamination. PC3 (human prostate cancer) cells were maintained in Roswell Park
Memorial Institute-1640 (RPMI-1640) media (2 g/L glucose) containing 10% (v/v) foetal bovine serum (FBS)
and 1% penicillin/streptomycin (growth medium). Human lung carcinoma A549 cells expressing an inducible
short hairpin RNA (shRNA) against eEF2K were generously provided by Janssen Pharmaceutica (Beerse,
Belgium) [15]. To induce the knockdown of eEF2K, A549 cells were cultured with 1 mM
isopropyl-β-D-1thiogalactopyranoside (IPTG) for 5 days prior to use. A549 cells were maintained in Dulbecco’s
modified Eagle medium media (4.5 g/L glucose) containing 10% (v/v) FBS and 1% penicillin/streptomycin.
NK-92 cells were cultured in α-MEM media containing 12.5% (v/v) FBS, 12.5% horse serum and 100 IU/ml
IL-2. All cells were cultured at 37°C in 5% CO2 and 95% air. For pH-buffered media, pH was adjusted by
adding NaHCO3.
After treatment, cells were lysed by scraping into ice-cold lysis buffer containing 1% (v/v) Triton X-100,
20 mM Tris–HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 2.5 mM Na2H2P2O7, 1 mM
β-glycerophosphate, 1 mM Na3VO4, 1 mM dithiothreitol and protease inhibitor cocktail, unless otherwise
stated. Lysates were spun at 4°C, 16 000×g for 10 min, the supernatants were kept and total protein concentra-
tions were quantified by Bradford assay (Bio-Rad, Gladesville, NSW, Australia) following the manufacturer’s
instructions. Normalised lysates were either kept at −20°C or subjected to further analysis.
Generation of CRISPR-directed eEF2K−/− cells
The eEF2K-KO CRISPR targeting vector was the GeneArt CD4 CRISPR Nuclease Vector (ThermoFisher
Scientific, Scoresby, VIC, Australia). The guide ssDNA sequence was 50-AGTGAGCGGTATAGCTCCAG-30.
PC3 cells were transfected with the CRISPR vector by nucleofection (Lonza, Mt Waverley, Australia). After
72 h, CD4-positive cells were enriched using magnetic CD4 Dynabeads (ThermoFisher Scientific) and then
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sorted into individual wells of 96-well plates using a BD FACSFusion flow cytometer (Becton, Dickinson &
Company, Wayville, SA, Australia). Positive clones were selected by immunoblotting analysis for the absence of
eEF2K and P-eEF2, and were further confirmed by Sanger sequencing analysis (Supplementary Figure S1; per-
formed by the Australian Genome Research Facility, Adelaide, Australia).
SDS–PAGE/WB analysis
Sodium dodecyl Sulfate-polyacrylamide gel electrophoresis (SDS–PAGE) and Western blot (WB) analysis were
performed as previously described [16]. Primary antibodies used were: New England Biolabs (NEB), Hitchin,
Herts, U.K.: PD-L1 (catalogue number 13684), eEF2 (2332), eIF4E (2067), ThermoFisher Scientific: P-eIF4E
Ser209 (44-528-G); Sigma–Aldrich: β-actin (A5316); Eurogentec, Seraing, Belgium: P-eEF2 Thr56 and eEF2K
(custom-made); Servicebio, Wuhan, Hubei, China: GAPDH (GB12002). Fluorescently tagged secondary anti-
bodies were from ThermoFisher Scientific. Blots were scanned using a LI-COR Odyssey imaging system
(Millenium Science, Mulgrave, Victoria, Australia). Blots were quantified using the LI-COR Image Studio Lite
4.0 software (LI-COR, Lincoln, NE, U.S.A.).
Plasmid and transfection
pICtest2 vector encoding StaCFluc with different start codons (AUG or CUG) were described previously [17].
PD-L1 50-UTR was introduced to the pICtest2 StaCFluc vector using the HindIII restriction site. Point muta-
tions were introduced by PCR mutagenesis using the Pfu DNA polymerase (Promega, Alexandria, VIC,
Australia). Cells were transfected using Lipofectamine® 3000 (Thermofisher Scientific, Adelaide, SA, Australia)
according to manufacturer’s instructions.
Polysome analysis
Polysome analysis was performed as described previously [18]. Briefly, 80% confluent cells grown on 10 cm
diameter culture dishes were lysed with 300 ml of lysis buffer [10 mM NaCl, 10 mM MgCl2, 10 mM Tris–HCl,
pH 7.5, 1% (v/v) Triton X-100, 1% sodium deoxycholate, 36 U/ml RNase inhibitor, 1 mM dithiothreitol] and
layered onto a 20–50% (w/v) sucrose gradient containing 30 mM Tris–HCl, pH 7.5, 100 mM NaCl and 10 mM
MgCl2, and centrifuged in a Beckman SW41 rotor for 150 min at 234 000×g. Fractions were collected while
monitoring absorbance at 254 nm. For RNA extraction, 1% (w/v) SDS and 0.15 mg/ml proteinase K were
added to each fractions, 1 : 3 (v/v) phenol:chloroform, pH 4.5, was then added to the samples to extract RNA,
and RNA was precipitated from the aqueous phase by the addition of 70% (v/v) isopropanol. RNA pellets were
washed once with 80% (v/v) ethanol before dissolving in RNase/DNase-free water for further analysis. For
qPCR analysis of sucrose gradient fractions, 1.2 kb kanamycin RNA provided by the reverse transcription kit,
used as an internal control for the reverse transcription (RT) reaction, was added to the RNA samples isolated
from each of the polysome fractions just before the RT.
Real-time quantitative RT-PCR (qPCR) amplification analysis
Total RNA was extracted using TRIzol (ThermoFisher Scientific). cDNA was produced using the QuantiNova
reverse transcription kit (Qiagen, Chadstone, VIC, Australia). For qPCR analysis of sucrose gradient fractions,
1.2 kb kanamycin RNA (Promega) was used as an internal control. qPCR was performed using the following
human primers (50–30): PD-L1: forward: TGGCATTTGCTGAACGCATTT; reverse: TGCAGCCAGGTCTAATT
GTTTT; B2M: forward: TGGGTTTCATCCATCCGACA, reverse: ACGGCAGGCATACTCATCTT. Samples
were analysed with PowerUp SYBR Green master mix (ThermoFisher Scientific) on an ABI Step One Plus
qPCR instrument (Applied Biosystems, Cheshire, U.K.). For total RNA analysis, ACTB (Forward: CATGTACG
TTGCTATCCAGGC; Reverse: CTCCTTAATGTCACGCACGAT) was used as the normalisation control. The
comparative threshold cycle (CT) method was applied to quantify mRNA levels.
Luciferase assays
Firefly luciferase (Fluc) activity was measured with luciferase reporter assay systems (Promega) on a
GloMax-discover multimode detection system (Promega) following the manufacturer’s instructions.
Flow cytometry analysis
Following treatment, cells were trypsinized and incubated with PD-L1 antibody [NEB, catalogue number
86744; 1 : 100 diluted in 0.1% BSA (w/v) in phosphate buffered saline (PBS)] for 30 min at 4°C, cells were
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washed thrice with PBS and then incubated with Alexa Fluor-conjugated rabbit secondary antibody (Abcam,
Melbourne, VIC, Australia) for 30 min. They were washed again thrice with PBS, the intensity of fluorescence
signals was recorded using FACS Canto™ II flow cytometry [Becton Dickinson (BD) Biosciences, North Ryde,
NSW, Australia], data were analysed using FlowJo software version 10.2 (BD Biosciences).
Lentiviral shRNA infection and NK-92 killing assays
Lentiviral non-targeting control (sh-NC) shRNA or shRNA targeting eEF2K (sh-eEF2K; sc-39011-V) were pur-
chased from Santa Cruz Biotechnology. Cells were infected with sh-NC, sh-eEF2K, positive clones were
screened by puromycin (8 μg/ml) selection. Cells were transfected with an empty vector (E.V.) or FLAG-eEF2K
[19] where indicated. 48 h later, 3500 cells per sample were seeded on 48-well plates overnight, NK-92 cells
were then added to cancer cells at a 5 : 1 ratio for 3 (for PC3) or 8 (for A549) h. NK-92 cells and cell debris
were removed by washing with PBS, and living cancer cells were then quantified by spectrometric analysis at
OD (570 nm), followed by crystal violet staining [20]. Before staining, we also took microscopic images of the
cells with a Cytation 5 multimode Reader (BioTek, Beijing, China). PD-1/PD-L1 Inhibitor 3 (Selleckchem,
Houston, TX, USA; S8158) was used as a positive control.
Cytokine assays
To assess levels of granzyme B, IFN-γ and perforin, 1 × 104 PC3 cells per sample were seeded on 96-well plates.
After 16 h, NK-92 cells were added to PC3 cells at a 5 : 1 ratio and cells were cultured further for another 12 h.
Cytokines from culture media were measured using the following ELISA kits (Dakewe Biotech, Shenzhen,
China) according to the manufacturer’s instructions: Granzyme B (1118502), Perforin (1118302), and IFN-γ
(1110002).
Gene expression and survival analysis from publicly available data
EEF2K and CD274 (PD-L1) gene expression and patient survival data were retrieved from Cancer Genome
Atlas (TCGA) and GEO (database: GSE56288) [21,22]. Kaplan–Meier survival curve and log rank tests were
performed using GraphPad Prism v7.06 software (GraphPad Software, Inc., San Diego, CA, U.S.A.).
Statistical analysis
Statistical analysis was performed using a one/two-way analysis of variance with the means of three independ-
ent experiments unless otherwise specified. GraphPad Prism (GraphPad Software, San Diego, CA, U.S.A.) soft-
ware package was used to calculate P-values. Results are means ± S.D. *: 0.01≤ P < 0.05; **: 0.001≤ P < 0.01;
***: P < 0.001.
Results
eEF2K promotes the translation of PD-L1
In some types of cells, the expression of PD-L1 is increased by interferon-γ (IFNγ [23]). IFNγ did indeed
increase the levels of the PD-L1 protein in prostate cancer PC3 (human prostate cancer) cells (Figure 1A, data
quantified in Figure 1B; note that PD-L1 generally appears as a rather fuzzy band on immunoblots, likely
reflecting the fact it is subject to multiple post-translational modifications [24]). Since no highly specific or
potent small-molecule inhibitor of eEF2K is yet available (even at high doses, the published compound
A484954 [25] only weakly inhibited the phosphorylation of eEF2; Figure 1A), we employed genetic approaches
to knock down or knock out the expression of eEF2K (see below for a description of the latter). We used
CRISPR–Cas9 genome editing to disrupt the EEF2K gene in PC3 cells (Supplementary Figure S1); as expected,
since eEF2K is the only kinase that phosphorylates the regulatory site, Thr56, in eEF2 [26], no phosphorylation
of eEF2 at this site was seen in eEF2K-KO PC3 cells (Figure 1A). eEF2K was also undetectable in the knockout
(KO) cells. eEF2K-KO showed lower levels of PD-L1 than the corresponding control cells (Figure 1A,B). IFNγ
effectively increased PD-L1 protein levels in the wild-type (WT) PC3 cells but not in eEF2K-KO cells. Thus,
eEF2K positively regulates the expression of the PD-L1 protein in PC3 cells.
A recent study reported that the MNK kinases, which phosphorylate another component of the protein syn-
thesis machinery, eIF4E, modulate the expression of PD-L1 [27]. However, at least in PC3 cells, inhibition of
the MNKs and thus of the phosphorylation of eIF4E using eFT508 [28] had no effect on PD-L1 protein levels
(Figure 1A).
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The key feature for immune-mediated killing of cancer cells is the amount of PD-L1 at the cell surface,
which we assessed by FACS analysis. Consistent with the data for total PD-L1, in PC3 cells, knocking out
eEF2K markedly decreased the amounts of PD-L1 detected at the cell surface, both in control cells and those
treated with IFNγ (Figure 1C, data are quantified in Figure 1D).
To achieve knockdown of eEF2K, we made use of previously described A549 cells harbouring an
IPTG-inducible shRNA against the EEF2K mRNA [26] (Supplementary Figure S2). Two stress conditions
which activate eEF2K, oxidative stress (H2O2) and acidosis (maintaining cells at pH 6.7, [15]) increased PD-L1
protein levels (Supplementary Figure S2A) in wild-type A549 cells. In contrast, PD-L1 protein levels trended
Figure 1. eEF2K upregulates PD-L1 protein expression in PC3 and A549 cells.
(A) Cells were cultured in the presence or absence of 100 mM A-484954, 100 nM eFT508 and/or 20 ng/ml IFNγ for 24 h. The
levels of indicated phospho- (P-) or total proteins were analysed by Western blotting. (B) Quantification of PD-L1 levels in A
(n = 3). (C) Cells were treated with 20 ng/ml IFNγ for 24 h before subjected to flow cytometry analysis of cell surface PD-L1
protein expression. Negative control indicates cells ‘stained’ without primary antibodies. (D) Quantification of C. (E) PC3 and (F)
A549 cells were treated with sh-NC or sh-eEF2K, or transfected with an empty vector (E.V.), or vectors encoding WT or KD
FLAG-eEF2K. Results are presented as means ± S.D.; **: 0.001≤ P < 0.01; ***: P < 0.001 (two-way ANOVA).
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 4371








niversity of Adelaide user on 25 August 2021
lower in eEF2K-KO A549 cells under all conditions tested and were significantly reduced in cells treated with
H2O2 or subjected to acidosis (Supplementary Figure S2A, quantified in Supplementary Figure S2B). [Note
that, upon activation, eEF2K is sometimes degraded (via the proteasome [19,29])]. Similarly, PD-L1 levels were
also reduced in eEF2K-null MDA-MB-231 cells (Supplementary Figure S2C,D) under conditions where eEF2K
is active (rapamycin treatment, H2O2 or acidosis). Conversely, ectopic expression of FLAG-tagged WT, but not
the kinase-dead (‘KD’, K170M, previously described in [30]) version of eEF2K, induced the expression of
PD-L1 in PC3 (Figure 1E) and A549 (Figure 1F) cells, in line with positive regulation of the expression of
PD-L1 by eEF2K. Knockdown of eEF2K had little or no effect on total PD-L1 mRNA levels in A549 cells
(Supplementary Figure S2E).
eEF2K promotes the association of the PD-L1 mRNA with polysomes
Given that the only known substrate for eEF2K is eEF2, the protein which mediates the translocation of the
elongation phase of mRNA translation, it seemed possible that eEF2K affected the translation of the PD-L1
mRNA. To assess this in PC3 cells, we resolved lysates from control or eEF2K-KO cells on sucrose density gra-
dients to separate non-polysomal mRNA from those associated with ribosomes or translationally active poly-
somes of various sizes which contain ribosomes actively translating mRNAs. Cells were treated with IFNγ prior
to lysis, to increase the levels of P-eEF2 (see Figure 1A). Knockout of eEF2K did not affect the overall propor-
tion of ribosomes in polysomes (Figure 2A,B) or the distribution of a ‘control’ mRNA (B2M), that encoding
β2-microglobulin (Figure 2E, quantified in Figure 2F). In marked contrast, 30% less of the PD-L1 mRNA was
found in active polysomes in samples from PC3 cells in which eEF2K had been knocked out (Figure 2C,D),
and much more was in fractions corresponding to inactive or poorly translated mRNAs. This could be because
residual eEF2K and P-eEF2 in IPTG-treated A549 cells were enough to sustain a sufficient basal level of trans-
lation of the PD-L1 mRNA and thus its steady-state levels.
Figure 2. Ablation of eEF2K shifts PD-L1 mRNAs from polysomal to non/subpolysomal fractions in PC3 cells.
(A) Cells were treated with 20 ng/ml IFNγ for 24 h before subjected to sucrose density gradient analysis; representative images
from three-independent experiments are shown. (B) The P/M (polysomal/non-polysomal) ratio from A was calculated by
integrating the areas under the polysomal and non-polysomal fractions. qPCR was performed using specific primers for human
(C and D) PD-L1 or (E and F) B2M. Positions of ribosomal/polysomal species are indicated. Results are presented as means ±
S.D.; *0.01≤ P < 0.05; **: 0.001≤ P < 0.01; ***: P < 0.001 (two-way ANOVA).
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Knockdown of eEF2K in A549 cells cultured with IFNγ did not affect the overall proportion of ribosomes in
polyribosomes (Supplementary Figure S3A), but RT-qPCR analysis of the fractions revealed that, while a sub-
stantial proportion of the PD-L1 mRNA was actively translated in control cells, there was almost no PD-L1
mRNA was in polysomal fractions in eEF2K-knockdown cells (Supplementary Figure S3B), whereas the distri-
bution of B2M was unaffected (Supplementary Figure S3C). Instead, the PD-L1 mRNA was found in the non-
polysomal regions of the gradient, indicating that it was barely translated under glucose starvation. Thus,
eEF2K promotes the association of the PD-L1 mRNA with active polyribosomes in both PC3 and A549 cells,
consistent with the observed changes in PD-L1 protein levels.
We noted that total PD-L1 mRNA levels were lower in eEF2K-KO PC3 cells, compared to control cells,
under basal, rapamycin-treated or oxidative or acidotic stress conditions or following IFNγ treatment
(Figure 3A,B). The PD-L1 mRNA is reported to have a short half-life [31]; it was therefore plausible that the
untranslated PD-L1 messages in eEF2K-KO cells were rapidly degraded in PC3 cells. Indeed, when transcription
of new mRNAs was blocked by actinomycin D, we observed that PD-L1 mRNA levels decreased faster in
eEF2K-null PC3 cells under both basal and IFNγ-treated conditions compared with the WT cells (Figure 3C,D),
indicating that the PD-L1 mRNA is less stable (has a shorter half-life) when eEF2K has been genetically deleted.
This presumably reflects the decreased translation and, as a consequence, the impaired stability (reviewed [32]),
of this mRNA under those conditions, explaining the differences in total PD-L1 mRNA between WT and
eEF2K-KO PC3 cells. However, we cannot formally exclude that eEF2K affects PD-L1 mRNA levels through
additional mechanisms, which may also help explain the differences between A549 and PC3 in terms of the
effect of knocking down or knocking out eEF2K on PD-L1 mRNA levels.
Figure 3. PD-L1 mRNAs are more rapidly degraded in eEF2K-null PC3 cells.
(A) Cells were cultured in in growth medium (control), or medium without FBS (no FBS), or medium without glucose (no
glucose), or in growth medium with the presence of 200 nM rapamycin or 3 mM H2O2, or medium buffered to pH 6.7; for 24 h.
(B) Cells were cultured in growth medium with or without 20 ng/ml IFNγ for 24 h. (C and D) Cells were cultured in growth
medium with or without 20 ng/ml IFNγ for 16 h, before the addition of 2 mg/ml actinomycin D. Cells were further incubated for
the indicated periods of time. (A–D): qPCR was performed to monitor the levels of PD-L1 mRNA. Results are presented as
means ± S.D. (n = 3); **: 0.001≤ P < 0.01; ***: P < 0.001 (two-way ANOVA).
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eEF2K enhances translation of the PD-L1 mRNA by bypassing translational
repression mediated by an upstream open reading frame (uORF)
Control of the translation of specific mRNAs is often mediated through features of their 50-untranslated region
(50-UTR, [33]). Regulatory elements such as upstream open reading-frames (uORFs) can modulate downstream
reinitiation at the start of the main coding region of an mRNA; in general, translation of the uORF represses
expression of the protein encoded by the main open reading-frame (ORF), although other scenarios may arise.
The human PD-L1 mRNA contains a single uORF which starts with CUG and partially overlaps the main
PD-L1 ORF (Figure 4A); this overlap means that translation of this uORF would prevent expression of PD-L1
protein as ribosomes would terminate translation of this uORF after the start of the main PD-L1 ORF. (In con-
trast, the mouse Pd-l1 mRNA contains three possible uORFs starting with either an AUG or a non-canonical
CUG (uCUG) [27]). We recently reported that active eEF2K, and thus slower elongation, favours the selection
of the canonical AUG as a start codon by augmenting the ability of ribosomes to distinguish between AUG
and near-cognate start codons [29].
We have previously developed ‘pICtest2’ dual-luciferase reporters with CUG as the start codon [17]. These
constructs were created encoding Fluc as well as a cistron encoding Renilla luciferase as an internal control.
eEF2K-KO PC3 cells were transfected with vectors expressing active Fluc from CUG or AUG as the start
codon. Following IFNγ treatment or under various stress conditions (glucose starvation, oxidative and acidotic
stress), eEF2K-KO PC3 cells exhibited a 2–3-fold higher levels of Fluc activity from the vector which has CUG
as the start codon than WT (eEF2K+/+) cells (Figure 4B). In contrast, the presence or absence of eEF2K did not
affect the Fluc levels observed with the vector which has AUG as the start of the Fluc cistron (Supplementary
Figure S4A) which is in line with our earlier data [29].
Next, we created a pICtest2 dual-luciferase reporter containing the full-length human PD-L1 50-UTR
(Figure 4C) and transfected it into WT and eEF2K-KO PC3 cells. IFNγ treatment or stress conditions (glucose
starvation, oxidative and acidotic stress) further enhanced Fluc activity in WT but not in eEF2K-KO or cells
treated with IFNγ plus eFT508 [27] (Figure 4C). In contrast, when transfected with a mutant vector where the
uCUG was mutated to CUC (which is not used as a start codon; PD-L1_uCUC construct, see Supplementary
Figure S4B) [27,34], WT and eEF2K-null PC3 cells exhibited similar levels of Fluc activity (data not shown and
Figure 4C). Notably, consistent with previous observations [27], disrupting the uCUG increased the reporter
activity by ∼80% in both WT and eEF2K-KO control cells indicating that it does indeed impair translation of
the main downstream ORF (Figure 4C). These data clearly indicate that active eEF2K favours higher rates of
initiation and translation of the main PD-L1 ORF, by slowing down elongation, enhancing the stringency of
start site selection and thus reducing translation of the inhibitory uORF (as depicted in the cartoon in
Figure 4D). We cannot absolutely rule out that there may be additional explanations for the ability of eEF2K to
enhance the synthesis of PD-L1.
Ablation of eEF2K enhances the ability of immune cell killing
We next sought to investigate whether the down-regulation of PD-L1 expression upon eEF2K ablation pro-
motes the capacity of immune cells to induce cancer cell death by performing immune killing assays. PD-1/
PD-L1 inhibitor 3 was used as a positive control [35]. To correct for any changes in total cell number due to
effects of proliferation or survival caused by knockdown of eEF2K, assay periods were kept short and, crucially,
for any given condition data are expressed as number of surviving cells with added NK cells/total remaining
cells without NK cells. Notably, both PC3 and A549 cells expressing sh-eEF2K, which express lower levels of
PD-L1 (Figure 1E,F) were more susceptible to immune killing by NK-92 cells than cells expressing sh-NC
(Figure 5A and Supplementary Figure S5; data presented as % cell survival ± NK cells to allow for any differ-
ences in total cell number). In terms of cancer cell survival, eEF2K only comes into play under conditions such
as low nutrient availability [6], acidosis [15] or hypoxia [26] (reviewed in [8,36]; Figure 5B and Supplementary
Figure S2A–D). Conversely, overexpression of FLAG-eEF2K, which increased the levels of PD-L1 protein
(Figure 1E,F) alleviated the cytotoxic effect of NK-92 cells towards PC3 and A549 cells (Figure 5A and
Supplementary Figure S5).
Consistent with these findings, as assessed by ELISA, levels of granzyme B, IFNγ and perforin in culture
media from PC3 cells overexpressing FLAG-eEF2K that had been co-cultured with NK-92 cells were lower
compared with medium from cells transfected with an empty vector (Figure 5B–D). Conversely, levels of these
cytokines from PC3 cells expressing sh-eEF2K and co-cultured with NK-92 cells were increased in comparison
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).4374
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with the sh-NC expressing ones (Figure 5B–D). These data further support the notion that overexpression of
eEF2K in cancer cells blunts the immune response whereas eEF2K depletion enhances the susceptibility of
cancer cells towards immune attack.
Figure 4. PD-L1 translation is up-regulated by eEF2K through a bypass of uORF-mediated translational repression in
PC3 cells.
(A) The sequence of the human PD-L1 50UTR which contains a conserved putative uORF in mouse. Start (CUG) and stop
(UGA) codons are in bold. (B) Cells were transfected with pICtest2 vectors encoding Fluc with CUG as a start codon. (C) Cells
were transfected with PD-L1_uCUG or PD-L1_uCUC. B (n = 8) and C (n = 12): 24 h after transfection, cells were cultured in
growth medium (control), treated with 20 ng/ml IFNγ (with or without 100 nM eFT508), or in medium without glucose (no
glucose/-Glu), or in growth medium with the presence of 3 mM H2O2 or in pH 6.7-buffered medium; for 16 h. Fluc activity was
then measured. Results are presented as ratios between Fluc and Rluc (means ± S.D.); **: 0.001≤ P < 0.01; ***: P < 0.001
(Student’s t-test). (D) Schematic representation of the mechanism by which eEF2K favours the selection of AUG over CUG as a
start codon. C: control.
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 4375
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Figure 5. eEF2K-null PC3 cells are more susceptible to immune killing.
PC3 cells were infected with sh-NC or sh-eEF2K, or transfected with an empty vector (E.V.) or FLAG-eEF2K. Forty-eight hours
later, cells were co-cultured with NK-92 cells for another 3 h, before being subjected to crystal violet staining (A). Cells treated
with PD-1/PD-L1 inhibitor 3 (10 mM) were used as a positive control. Data are graphed as surviving cells ± NK cells, to
compensate for possible differences in total cell number arising from altered eEF2K levels. Culture supernatants from
A were also harvested after 12 h and analysed by ELISA for (B) granzyme B, (C) IFN-γ or (D) perforin. Results are shown as
means ± S.D., n = 3. *0.01≤ P < 0.05, ** 0.001≤ P < 0.01 (one-way ANOVA). For simplicity, not all instances of statistical
significance are shown.
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).4376
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Gene expression profiles of EEF2K and CD274 (PD-L1) in a database of
prostate cancer patients
In addition, gene expression profiles retrieved from the TCGA (Figure 6A) and Grasso (Figure 6B) databases
have demonstrated that the expression levels of EEF2K and CD274, which encodes PD-L1, are positively corre-
lated in tumour samples obtained from prostate cancer patients [21,22]. Notably, high levels of EEF2K expres-
sion were associated with decreased overall survival of prostate cancer patients (Figure 6C). High levels of
CD274 expression were also associated with decreased progression-free survival of lung cancer patients
(Figure 6D). In contrast, low levels of EEF2K expression were associated with lower progression-free survival of
lung cancer patients (data not shown). This is in line with the fact that the role of eEF2K in cancer develop-
ment is complex as revealed by apparently conflicting reports, which suggest eEF2K may promote or impair
tumour growth or survival. For example, we recently reported that depletion of eEF2K promotes growth of
A549 xenografts in mice [37]. In direct contrast, eEF2K is also highly expressed in other cancers (see, e.g.
[38,39] and is also activated under conditions (such as nutrient depletion or hypoxia [8]) which occur within
solid tumours; this will permit the enhanced expression of PD-L1 increasing the resistance of the tumour cells
to immune attack.
Discussion
Here we show that eEF2K positively regulates the levels of the major immune checkpoint protein, PD-L1 in
three different types of cancer cells (A549, PC3 and MDA-MB-231) and provide evidence that this occurs at
the level of the translation of its mRNA. This adds to the growing evidence that eEF2K helps to promote
Figure 6. High levels of EEF2K positively correlate with enhanced CD274 gene expression and poor survival rates in
cancer patients.
(A) Pearson’s correlation analysis between the expression of EEF2K and CD274 in TCGA (prostate cancer) and, (B) Grasso
datasets (prostate cancer). Kaplan–Meier plots showing overall survival in (C) prostate cancer and (D) progression-free survival
in lung adenocarcinoma with low/high EEF2K (C) or CD274 (D), respectively. Data were obtained from TCGA datasets. Patients
were stratified into two groups, according to the level of mRNA expression of EEF2K or CD274. Data were statistically analysed
using a two-sided log-rank test.
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tumour growth and metastasis, providing further impetus to the concept that eEF2K (a non-essential and atyp-
ical protein kinase) is an attractive target for the therapy of at least some types of solid tumours [8–10,40].
eEF2K is activated under conditions which occur within tumours, such as nutrient depletion [6] or hypoxia [26];
this will also facilitate the production of PD-L1 and thus enhance the tumour’s resistance to immune attack.
Further work, using e.g. murine models, will be needed to explore the role of eEF2K in protecting tumour cells
from immune surveillance in vivo; as our cancer cells in which eEF2K has been depleted or knocked out are of
human origin, we are currently unable to perform such studies which require immunocompetent mice.
Inhibition of mTORC1 and its substrate S6K, both of which are negative regulators of eEF2K [41,42], has
also been shown to promote the synthesis of PD-L1 in lung cancer cells [43], although in that case this was
attributed to effects on the stability of the PD-L1 protein. Furthermore, the mTOR inhibitor everolimus also
increases PD-L1 expression in renal cell carcinoma lines [44], an effect which, at least in part, might involve
the activation of eEF2K. In contrast, in several mutant EGFR (EGFRL858R/T790M) and KRas (KRasLA2 and
KRasG12D) murine lung cancer models, active AKT-mTOR signalling actually increases PD-L1 expression [45].
Therefore, the impact of particular signalling pathways such as mTORC1 (and thus upstream PI 3-kinase
signalling) on PD-L1 expression differs substantially between types of cancers or cancer cells [43–45].
While two earlier studies reported direct or indirect translational control of the regulation of PD-L1 protein
levels, our findings are quite distinct, since, given that eEF2 is the only validated substrate for eEF2K, our data
point to direct control of the translation of the PD-L1 via control of translation elongation. Furthermore, our
data provide the first example of control of translation of a uORF-containing mRNA via regulation of the trans-
lation elongation machinery. Thus, while eEF2K inhibits general protein synthesis, it can actually enhance the
synthesis of PD-L1; in fact, there are now several published examples where eEF2K stimulates the translation of
specific mRNAs [9,11,18]. Given that uORFs with a non-canonical CUG start codon appear to exist in many
mRNAs [13], eEF2K may control the translation of certain other mRNAs in a similar way. Furthermore, there
is a very well-known system whereby a phosphorylation event on another translation factor, eIF2, inhibits
overall translation but actually promotes translation of some mRNAs [46]. Thus, two different mechanisms
involving inhibitory phosphorylation of an initiation factor (eIF2) or elongation factor (eEF2), which generally
operate to slow down the translation, can actually promote translation of specific mRNAs, by virtue of features
of their uORFs. Since eEF2K and the kinases that phosphorylate eIF2 are activated under different circum-
stances [3,46], these mechanisms are poised to modulate the synthesis of specific proteins under distinct
conditions.
In the study by Cerezo et al. [47], in melanoma, the eIF4F translation initiation factor complex was shown to
positively regulate the translation of the mRNA encoding the transcription factor STAT1 and thus the induc-
tion of the PD-L1 mRNA in response to IFNγ. Another study, on KRAS-driven liver cancer [27], also provided
evidence that PD-L1 expression is controlled through eIF4F, but in this case through its direct control of the
translation of the mRNA for PD-L1 through the phosphorylation of another component of that complex,
eIF4E. We did test the same MNK inhibitor as Xu et al. [27], eFT508 [28], but saw no significant effect on
PD-L1 protein levels in PC3 (Figure 1A) or A549 (data not shown) cells. It thus appears that control of PD-L1
expression by the MNKs is restricted to some kinds of (cancer) cells.
An important implication of our data, together with other recent findings [27,47] is that the translational
regulatory networks somehow steer events to aid cancer cells to evade immunosurveillance by increasing the
synthesis of immune checkpoints, and thus promote tumour cell migration and metastasis. In particular, the
previously reported PD-L1 50-UTR serves to allow cancer cells utilise regulators of mRNA translation, e.g.
eEF2K, to increase the levels of a ‘cloak of invisibility’ — PD-L1 — and thereby hide themselves from immune
attack. Specifically, the human PD-L1 50-UTR contains a conserved uORF which starts with a non-canonical
start codon (CUG). The uORF partially overlaps with and inhibits the translation of the main ORF encoding
PD-L1 [27]. We previously showed that activation of eEF2K helps reduce initiation at non-canonical start sites,
i.e. CUG or GUG [29]. Impaired elongation slows down ribosomes within the main ORF and thus allows more
time for selection of the optimal choice — an AUG start codon. Thus, by reducing initiation at the inhibitory
uORF, eEF2K can promote translation of the main ORF and thus the production of PD-L1, as observed in our
experiments. Our findings identify for the first time a specific feature of an mRNA which confers positive
control of its translation by eEF2K. Since a substantial number of other mRNAs possess uORFs, and some of
them may also be subject to translational control by eEF2K, although this is likely depends on other features
such as the location of the uORF within the 50-UTR and the nature of its start codon and its immediate
context.
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To further support the notion that the immune checkpoint is tightly regulated by translation elongation, the
present study also demonstrates for the first time a positive correlation between EEF2K and CD274 levels in
prostate cancer patients. Aberrantly increased EEF2K levels in prostate or lung cancer patients also predict poor
survival. Importantly, our data show that depletion of eEF2K enhances the susceptibility of cancer cells to
NK-cell mediated toxicity. Unfortunately, we cannot use immunocompetent mouse models to test these effects
in vivo, as the available eEF2K-KO cell lines are of human origin.
Taken together with the roles of eEF2K in promoting the survival of cancer cells under nutrient-deprived
conditions [6,38,39], in cell migration and cancer cell metastasis [9], and in angiogenesis [10], our present data
add further support to the conclusion that disabling eEF2K may be a valuable therapeutic approach to tackling
established solid tumours, at least for some types of cancers. However, as is the case with targeting other pro-
cesses such as autophagy and mTORC1 signalling [2,48,49], in some specific settings the inhibition of eEF2K
may actually promote cancer-related processes, e.g. tumour initiation. Blocking eEF2K function may be more
appropriate in later stages of tumour progression although this may also depend on the genetic and/or meta-
bolic profile of the tumour. Our data further highlight the multi-faceted role played by eEF2K in regulating
protein expression and cellular functions in cancer cells.
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